U.S., Feb. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07389356) titled 'Modified R-MINE Regimen vs. R-GemOx Regimens on the Treatment of Late Relapsed DLBCL' on Dec. 17, 2025.
Brief Summary: This study was a multicenter, open, randomized controlled, phase II clinical study. Is expected in 70 cases of late relapsed diffuse large B cell lymphoma, were randomly assigned to receive mitoxantrone liposomes modified R - MINE plan or R - GemOx treatment. Each cycle was 3 weeks (21 days) for a total of 4 cycles. Subjects assigned to each signed informed consent to screening, screening, in the center of the study determined in accordance with the order signed informed consent. Before the start of the trial, the nu...